Canaccord analyst William Plovanic lowered the firm’s price target on Inari Medical to $75 from $79 and keeps a Buy rating on the shares. The firm said the VTE market remains under-penetrated, and they believe the company’s pipeline of products and strong clinical body of data will support its strong position.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NARI:
- Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
- Inari Medical initiated with a Buy at Needham
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
- Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
- Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M